Lipfendra (enlicitide) is a once-daily pill that the FDA approved on July 16, 2026, to lower LDL (“bad”) cholesterol in adults with high cholesterol, including a genetic form called heterozygous familial hypercholesterolemia (HeFH). It works by blocking a protein called PCSK9, and it’s the first oral drug in its class — every other PCSK9 inhibitor on the market is an injection.
Why it matters:
- No needles. It replaces injectable PCSK9 inhibitors with a tablet you swallow once a day.
- Strong LDL reduction. Clinical trials showed placebo-adjusted LDL-C drops of 56–59%.
- Works alongside statins. It’s designed as an add-on for people who still have high LDL despite taking a statin.
Keep reading for dosage, side effects, trial data, and how Lipfendra stacks up against Repatha and Praluent.
Lipfendra Development and Approval Timeline
Phase 2b Results Published
LDL-lowering results published in JACC and announced by Merck.
Phase 3 CORALreef Trials
CORALreef Lipids and HeFH studies officially began.
FDA Approval
Lipfendra became the first oral PCSK9 inhibitor approved by the FDA.
What Is Lipfendra (Enlicitide)?
Lipfendra is the brand name for enlicitide, a drug Merck developed under the research code MK-0616. It’s a macrocyclic peptide — a ring-shaped molecule — engineered to attach to PCSK9 and stop it from working. Merck markets it as LIPFENDRA® in 20 mg tablets.
Until this approval, patients who needed a PCSK9 inhibitor had to use injectable drugs like Repatha or Praluent. Lipfendra changes that by putting PCSK9 inhibition into pill form for the first time.
What Is Lipfendra Used For?
The FDA approved Lipfendra as an adjunct to diet and exercise to lower LDL cholesterol in adults with:
- Hypercholesterolemia (high LDL cholesterol), including patients already on a statin who need further LDL lowering
- Heterozygous familial hypercholesterolemia (HeFH), an inherited condition that causes very high LDL from a young age
It is not a first-line treatment. Doctors typically prescribe it for patients whose LDL remains too high despite moderate- or high-intensity statin therapy, with or without other cholesterol drugs.
How Does Lipfendra Work?
Lipfendra targets PCSK9, a protein your liver makes that normally breaks down LDL receptors. Fewer LDL receptors means your liver can pull less LDL cholesterol out of your bloodstream, so LDL levels rise.
Enlicitide binds to PCSK9 and blocks it from attaching to LDL receptors. With PCSK9 out of the way, your liver keeps more LDL receptors on its surface, clears more LDL from your blood, and your LDL-C level drops.
This is the same basic mechanism used by injectable PCSK9 inhibitors — Lipfendra just delivers it through a peptide that survives digestion well enough to work as a pill.
Lipfendra Dosage
- Standard dose: 20 mg, taken by mouth once daily
- Use: As an add-on to diet, exercise, and (in most patients) an existing statin
- Your doctor will decide whether you also need to stay on other lipid-lowering therapy
Never change your statin regimen or stop a cholesterol medication because you’ve heard about Lipfendra — talk to your prescribing doctor first.
Clinical Trial Results
The FDA approval rests on two Phase 3 trials from Merck’s CORALreef program, comparing Lipfendra to placebo over 24–52 weeks.
| Trial | Population | LDL-C reduction vs. placebo (Week 24) | ApoB reduction | Non-HDL-C reduction |
|---|---|---|---|---|
| CORALreef Lipids (n=2,904) | Adults with hypercholesterolemia | 56% | 50% | 54% |
| CORALreef HeFH (n=303) | Adults with familial hypercholesterolemia | 59% | 48% | 52% |
Both reductions were statistically significant (p<0.001). A related Phase 2b trial published in the peer-reviewed literature found dose-dependent LDL-C reductions of up to roughly 61% at the highest dose tested.
“In two Phase 3 trials, LIPFENDRA led to impressive reductions in LDL-C.” — Dr. Ann Marie Navar, cardiologist at UT Southwestern Medical Center and lead investigator on the CORALreef Lipids trial
It’s worth noting: LDL-lowering is a surrogate marker. A separate, larger trial — CORALreef Outcomes, enrolling more than 14,500 participants — is still underway to confirm whether Lipfendra actually reduces heart attacks and strokes, not just cholesterol numbers.
Lipfendra Side Effects
In the CORALreef Lipids trial, side effects with Lipfendra were similar to placebo overall. In the CORALreef HeFH trial, two side effects showed up more often with Lipfendra than placebo:
| Side effect | Lipfendra | Placebo |
|---|---|---|
| Diarrhea | 7% | 2% |
| Dizziness | 9% | 4% |
Key safety points:
- Similar numbers of patients stopped treatment because of side effects in both the Lipfendra and placebo groups — meaning the drug was generally well tolerated.
- No new or unexpected safety signals emerged compared to earlier trials.
- This list covers only the most common reactions from the pivotal trials. For the complete list, see the official Prescribing Information and Medication Guide linked in the References section below.
Who Should Not Take Lipfendra
Talk to your doctor before starting Lipfendra if you:
- Are pregnant, breastfeeding, or planning pregnancy
- Have severe kidney or liver problems (ask whether dosing needs adjustment)
- Are taking other cholesterol medications, since your regimen may need to change
- Have had an allergic reaction to enlicitide or any of its ingredients
This is general information, not a complete list of precautions. Your doctor needs your full medical history to determine if Lipfendra is right for you.
Lipfendra vs. Repatha vs. Praluent
| Feature | Lipfendra (enlicitide) | Repatha (evolocumab) | Praluent (alirocumab) |
|---|---|---|---|
| Form | Oral tablet | Injection | Injection |
| Frequency | Once daily | Every 2–4 weeks | Every 2–4 weeks |
| Drug class | PCSK9 inhibitor (peptide) | PCSK9 inhibitor (antibody) | PCSK9 inhibitor (antibody) |
| Needle required | No | Yes | Yes |
The biggest practical difference is the needle-free, once-daily format. Effectiveness looks broadly comparable on paper, but head-to-head trial data between Lipfendra and the injectable drugs isn’t yet available.
How Much Does Lipfendra Cost?
Merck has said it plans to price Lipfendra at roughly $10.50 per day for a one-month supply. As with most brand-name drugs, your actual out-of-pocket cost will depend on your insurance coverage and any manufacturer assistance programs.
FAQs
Is Lipfendra a statin? No. Statins work by blocking cholesterol production in the liver. Lipfendra works differently, by blocking the PCSK9 protein. It’s meant to be added to a statin, not to replace one, in most patients.
How fast does Lipfendra lower cholesterol? Trial data measured LDL-C reduction at 24 weeks, but PCSK9 inhibitors typically start lowering LDL within the first few weeks of use. Your doctor will recheck your lipid panel to confirm your response.
Does Lipfendra prevent heart attacks? That hasn’t been proven yet. It’s proven to lower LDL cholesterol, and lower LDL is strongly linked to lower cardiovascular risk in general, but the dedicated outcomes trial for Lipfendra is still ongoing.
Can I take Lipfendra instead of my statin? Don’t stop a statin without talking to your doctor first. Lipfendra was studied as an add-on therapy, not a statin replacement.
Also read: Thousands Sick: The Parasite Causing Explosive Diarrhea in 2026
Disclaimer: The information in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider before starting any new medication or health routine.
